• Global call launched to tackle retinal drug delivery challenges
    The initiative targets critical challenges in ophthalmic drug development.

Research news

Global call launched to tackle retinal drug delivery challenges

BioMed X and Boehringer Ingelheim are expanding their joint XSeed Labs incubator in Ridgefield, Connecticut, with the launch of a second research group focused on next-generation intraocular biologics.

The new initiative aims to address the need for longer-lasting treatments for retinal diseases - specifically reducing the burden of frequent intraocular injections. A global call for proposals invites researchers to develop novel biologic platforms that combine extended intraocular activity with deep retinal penetration.

The selected team will work independently on-site to explore new design principles, develop a high-throughput human in vitro model for screening candidate biologics, and validate the most promising leads in preclinical models.

“Our goal is to push the boundaries of biologics design in ophthalmology,” said Mark Johnston, CEO of BioMed X USA. “This collaboration brings academic creativity into direct alignment with pharmaceutical innovation.”

The call is open to early-career researchers with expertise in ophthalmology, tissue engineering, or antibody discovery. Proposals must be submitted by 12 July 2025, via the BioMed X Career Space. 

More information online
 


Digital Edition

ILM Guide 2025/26

June 2025

Buyers' Guide Listings- Product Listings by Category- Suppliers Listings (A-Z)Chromatography Articles- Setting the power coefficient and the baseline to linearise the signal of the evaporative ligh...

View all digital editions

Events

Forensics Europe Expo

Jun 18 2025 London, UK

AUTOMATICON

Jun 24 2025 Warsaw, Poland

CPhI & P-MEC China 2025

Jun 24 2025 Shanghai, China

Discovery & Development Europe 2025

Jul 01 2025 Basel, Switzerland

MMC 2025

Jul 01 2025 Manchester, UK

View all events